查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
非感染性黄斑水肿治疗的全球市场 - 全球产业分析、规模、份额、成长、趋势和预测（2031） - 按药物类型、按适应症、按给药途径、按分销管道、按地区
市场调查报告书
商品编码
1410591

非感染性黄斑水肿治疗的全球市场 - 全球产业分析、规模、份额、成长、趋势和预测（2031） - 按药物类型、按适应症、按给药途径、按分销管道、按地区

Non-infectious Macular Edema Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:
出版日期: | 出版商: Fairfield Market Research | 英文 323 Pages | 商品交期: 2-5个工作天内

价格
简介目录

一项开创性的研究揭示了全球非感染性黄斑水肿治疗市场的重大发展。 各地区糖尿病相关併发症的迅速增加以及人们对眼部相关疾病的认识不断提高，推动了对黄斑水肿有效治疗的需求不断增长。 需求激增导致市场上治疗选择激增，包括抗 VEGF 药物、皮质类固醇、免疫抑制剂和生物製剂。 抗 VEGF 疗法传统上占据市场主导地位，预计在预测期内将保持较高的市场份额。

然而，由于人们对抗 VEGF 药物相关潜在副作用的认知不断增强，因此预计抗 VEGF 药物市场的使用量将逐渐下降。 全身性免疫调节治疗可减少对抗 VEGF 药物的依赖。 值得注意的是，未来几年对皮质类固醇的需求预计将激增，并且市场预计在预测期内将呈指数级增长。

最近核准用于治疗黄斑水肿的玻璃体内植入物是市场成长的催化剂。 玻璃体内注射的采用正在增加，特别是在北美，随着三种新产品的推出：Eylea、Ozurdex 和 Iluvien。 在北美和欧洲国家，直到2012年Lucentis上市之前，玻璃体内注射尚未广泛使用，雷射光凝固是主要的治疗方法。

越来越多地采用玻璃体内注射疗法是由于玻璃体内皮质类固醇植入物在低剂量下非常有效。 患者越来越多地使用玻璃体内植入物，推动了全球对黄斑水肿治疗的需求。

免疫抑制治疗常与皮质类固醇合併使用，在黄斑水肿的治疗中扮演重要角色。 这些治疗剂通常添加到皮质类固醇治疗方案中以减少对大剂量类固醇的需求，或者当类固醇治疗不能很好耐受时单独使用作为类固醇节省剂。

虽然市场显示出巨大的成长潜力，但挑战仍然存在。 许多患者和眼科医师正在选择替代治疗，而不是抗 VEGF 和皮质类固醇药物。 对于糖尿病黄斑水肿 (DME) 患者，由于错过注射而不遵守治疗计划可能会导致不可逆的损伤和永久性视力丧失。

此外，全球市场上很容易买到假药和标籤外药品。 几种重磅抗 VEGF 药物的生物相似药的推出预计将透过减少品牌和专利药物的使用来进一步影响市场。

本报告调查了全球非感染性黄斑水肿治疗市场，按药物类型、适应症、给药途径、分销管道、地区和市场参与者提供了市场概述。它提供了资讯企业的竞争趋势。

目录

第 1 章执行摘要

第二章市场概述

  • 市场定义与细分
  • 市场动态
  • 价值链分析
  • 波特五力分析
  • 新冠肺炎 (COVID-19) 影响分析
  • 乌克兰和俄罗斯之间衝突的影响
  • 经济概况
  • 杵分析

第三章2018-2023年生产与贸易统计

第 4 章价格分析，2018-2023

第五章2018-2031年全球非感染性黄斑水肿治疗市场前景

  • 全球非感染性黄斑水肿治疗市场前景，按药物类型、价值（百万美元）和数量（2018-2031 年）划分
  • 全球非感染性黄斑水肿治疗市场前景，按适应症、价值（百万美元）和数量（2018-2031 年）划分
  • 全球非感染性黄斑水肿治疗市场前景、给药途径、价值（百万美元）和数量（2018-2031 年）
  • 全球非感染性黄斑水肿治疗市场展望，依通路、价值（百万美元）、销售量（2018-2031 年）
  • 全球非感染性黄斑水肿治疗市场展望，按地区、价值（百万美元）、销售量（2018-2031 年）

第6章北美非感染性黄斑水肿治疗市场前景，2018-2031

第 7 章欧洲非感染性黄斑水肿治疗市场前景，2018-2031

第 8 章亚太地区非感染性黄斑水肿治疗市场前景，2018-2031

第 9 章拉丁美洲非感染性黄斑水肿治疗市场展望，2018-2031

第10章中东及非洲非感染性黄斑水肿治疗市场前景，2018-2031

第十一章竞争态势

  • 产品和指示热图
  • 2023 年公司市占率分析
  • 竞争力仪表板
  • 公司简介
    • Pfizer, Inc.
    • Novartis AG
    • F. Hoffman - La Roche Ltd.
    • AbbVie Inc
    • Bayer AG
    • Valeant Pharmaceuticals Inc
    • Alimera Sciences Inc
    • Clearside Biomedical, Inc

第12章附录

简介目录

A groundbreaking study has shed light on a remarkable development in the global non-infectious macular edema treatment market. The surge in diabetes-related complications and increased awareness of eye-related ailments across various regions have fueled a growing demand for effective treatments for macular edema. This surge in demand has led to a proliferation of treatment options in the market, including Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics, and more. Anti-VEGF treatments have traditionally dominated the market, and they are expected to maintain the highest market share during the forecast period.

Transition Away from Anti-VEGF Toward Corticosteroids

However, the Anti-VEGF market is anticipated to witness a gradual decline in usage due to heightened awareness of potential side effects associated with the drug. Systemic immunomodulatory treatment is poised to reduce reliance on Anti-VEGF medications. Notably, Corticosteroids are projected to experience an exceptional surge in demand in the coming years, with the market expected to grow at a stellar rate during the forecast period.

Intravitreal Implants and Immunosuppressants Triggering Market Growth

The recent approval of Intravitreal Implants for macular edema treatment has catalyzed market growth. The introduction of three new products - Eylea, Ozurdex, and Iluvien - has led to increased adoption of intravitreal medications, particularly in North America. Intravitreally injected medications were less commonly used in North America and European countries, where laser photocoagulation was the primary treatment method before the launch of Lucentis in 2012.

The rising adoption of Intravitreal therapies can be attributed to the availability of low-dose, high-efficacy corticosteroid implants for Intravitreal use. Patients are increasingly turning to Intravitreal implants, driving global demand for macular edema treatment.

Immunosuppressant Therapies Enhance Treatment Efficacy

Immunosuppressant therapies, often used in conjunction with corticosteroids, play a vital role in the treatment of macular edema. These therapies are typically added to corticosteroid regimens to reduce the need for high doses of systemic steroids or used independently as steroid-sparing agents when steroid treatment is not well-tolerated.

For example, three immunomodulators - methotrexate (Rheumatrex), azathioprine (Imuran), and mycophenolate mofetil (MMF, Cellcept) - have proven to be highly effective in achieving disease quiescence and are well-tolerated by patients. These immunosuppressants have emerged as efficient treatment options, driving demand in the global market for non-infectious macular edema treatment.

Challenges in the Global Macular Edema Market

While the market exhibits significant growth potential, challenges persist. Many patients and ophthalmologists opt for alternative treatments over Anti-VEGF and corticosteroids due to the repeated injections and high costs associated with these drugs. Non-compliance with treatment schedules, resulting in missed injections, can lead to irreversible damage and permanent vision loss in diabetic macular edema (DME) patients.

Additionally, counterfeit and off-label drugs are readily available in the global market. The launch of biosimilars for some blockbuster anti-VEGF agents is expected to further impact the market by reducing opportunities for branded and patented drugs.

Market Segmentation

Drug Type

  • Anti-VEGF
  • Corticosteroids
  • Immunosuppressant
  • Biologics
  • Others

Indication

  • Non-infectious Uveitic Macular Edema
  • Diabetic Macular Edema
  • Retinal Vein Occlusion with Macular Edema

Route of Administration

  • Oral
  • Parenteral
  • Topical

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region

  • North America
  • Latin America
  • Europe
  • Japan
  • MEA
  • APAC

Table of Contents

1. Executive Summary

  • 1.1. Global Non-infectious Macular Edema Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value and Volume, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Production Output and Trade Statistics, 2018 - 2023

  • 3.1. Global Non-infectious Macular Edema Treatment Market Production Output, by Region, Value (US$ Mn), 2018 - 2023
    • 3.1.1. North America
    • 3.1.2. Europe
    • 3.1.3. Asia Pacific
    • 3.1.4. Latin America
    • 3.1.5. Middle East and Africa

4. Price Analysis, 2018 - 2023

  • 4.1. Global Average Price Analysis, by Drug Type/ Material, US$ Per Unit, 2018 - 2023
  • 4.2. Prominent Factor Affecting Non-infectious Macular Edema Treatment Prices
  • 4.3. Global Average Price Analysis, by Region, US$ Per Unit

5. Global Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031

  • 5.1. Global Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Anti-VEGF
      • 5.1.1.2. Corticosteroids
      • 5.1.1.3. Immunosuppressant
      • 5.1.1.4. Biologics
      • 5.1.1.5. Others
  • 5.2. Global Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Non-infectious Uveitic Macular Edema
      • 5.2.1.2. Diabetic Macular Edema
      • 5.2.1.3. Retinal Vein Occlusion with Macular Edema
  • 5.3. Global Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Oral
      • 5.3.1.2. Parenteral
      • 5.3.1.3. Topical
  • 5.4. Global Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Hospital Pharmacies
      • 5.4.1.2. Retail Pharmacies
      • 5.4.1.3. Online Pharmacies
  • 5.5. Global Non-infectious Macular Edema Treatment Market Outlook, by Region, Value (US$ Mn) and Volume, 2018 - 2031
    • 5.5.1. Key Highlights
      • 5.5.1.1. North America
      • 5.5.1.2. Europe
      • 5.5.1.3. Asia Pacific
      • 5.5.1.4. Latin America
      • 5.5.1.5. Middle East & Africa

6. North America Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031

  • 6.1. North America Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Anti-VEGF
      • 6.1.1.2. Corticosteroids
      • 6.1.1.3. Immunosuppressant
      • 6.1.1.4. Biologics
      • 6.1.1.5. Others
  • 6.2. North America Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Non-infectious Uveitic Macular Edema
      • 6.2.1.2. Diabetic Macular Edema
      • 6.2.1.3. Retinal Vein Occlusion with Macular Edema
  • 6.3. North America Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Oral
      • 6.3.1.2. Parenteral
      • 6.3.1.3. Topical
  • 6.4. North America Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. Hospital Pharmacies
      • 6.4.1.2. Retail Pharmacies
      • 6.4.1.3. Online Pharmacies
  • 6.5. North America Non-infectious Macular Edema Treatment Market Outlook, by Country, Value (US$ Mn) and Volume, 2018 - 2031
    • 6.5.1. Key Highlights
      • 6.5.1.1. U.S. Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 6.5.1.2. U.S. Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 6.5.1.3. U.S. Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 6.5.1.4. U.S. Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 6.5.1.5. Canada Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 6.5.1.6. Canada Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 6.5.1.7. Canada Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 6.5.1.8. Canada Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Europe Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031

  • 7.1. Europe Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Anti-VEGF
      • 7.1.1.2. Corticosteroids
      • 7.1.1.3. Immunosuppressant
      • 7.1.1.4. Biologics
      • 7.1.1.5. Others
  • 7.2. Europe Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Non-infectious Uveitic Macular Edema
      • 7.2.1.2. Diabetic Macular Edema
      • 7.2.1.3. Retinal Vein Occlusion with Macular Edema
  • 7.3. Europe Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Oral
      • 7.3.1.2. Parenteral
      • 7.3.1.3. Topical
  • 7.4. Europe Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Hospital Pharmacies
      • 7.4.1.2. Retail Pharmacies
      • 7.4.1.3. Online Pharmacies
  • 7.5. Europe Non-infectious Macular Edema Treatment Market Outlook, by Country, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.5.1. Key Highlights
      • 7.5.1.1. Germany Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.2. Germany Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.3. Germany Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.4. Germany Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.5. U.K. Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.6. U.K. Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.7. U.K. Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.8. U.K. Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.9. France Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.10. France Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.11. France Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.12. France Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.13. Italy Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.14. Italy Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.15. Italy Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.16. Italy Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.17. Turkey Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.18. Turkey Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.19. Turkey Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.20. Turkey Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.21. Russia Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.22. Russia Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.23. Russia Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.24. Russia Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.25. Rest of Europe Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.26. Rest of Europe Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.27. Rest of Europe Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.28. Rest of Europe Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031

  • 8.1. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Anti-VEGF
      • 8.1.1.2. Corticosteroids
      • 8.1.1.3. Immunosuppressant
      • 8.1.1.4. Biologics
      • 8.1.1.5. Others
  • 8.2. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Non-infectious Uveitic Macular Edema
      • 8.2.1.2. Diabetic Macular Edema
      • 8.2.1.3. Retinal Vein Occlusion with Macular Edema
  • 8.3. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Oral
      • 8.3.1.2. Parenteral
      • 8.3.1.3. Topical
  • 8.4. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. Hospital Pharmacies
      • 8.4.1.2. Retail Pharmacies
      • 8.4.1.3. Online Pharmacies
  • 8.5. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, by Country, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.5.1. Key Highlights
      • 8.5.1.1. China Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.2. China Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.3. China Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.4. China Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.5. Japan Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.6. Japan Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.7. Japan Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.8. Japan Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.9. South Korea Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.10. South Korea Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.11. South Korea Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.12. South Korea Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.13. India Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.14. India Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.15. India Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.16. India Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.17. Southeast Asia Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.18. Southeast Asia Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.19. Southeast Asia Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.20. Southeast Asia Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.21. Rest of Asia Pacific Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.22. Rest of Asia Pacific Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.23. Rest of Asia Pacific Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.24. Rest of Asia Pacific Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Latin America Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031

  • 9.1. Latin America Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 9.1.1. Key Highlights
      • 9.1.1.1. Anti-VEGF
      • 9.1.1.2. Corticosteroids
      • 9.1.1.3. Immunosuppressant
      • 9.1.1.4. Biologics
      • 9.1.1.5. Others
  • 9.2. Latin America Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 9.2.1. Key Highlights
      • 9.2.1.1. Non-infectious Uveitic Macular Edema
      • 9.2.1.2. Diabetic Macular Edema
      • 9.2.1.3. Retinal Vein Occlusion with Macular Edema
  • 9.3. Latin America Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 9.3.1. Key Highlights
      • 9.3.1.1. Oral
      • 9.3.1.2. Parenteral
      • 9.3.1.3. Topical
  • 9.4. Latin America Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 9.4.1. Key Highlights
      • 9.4.1.1. Hospital Pharmacies
      • 9.4.1.2. Retail Pharmacies
      • 9.4.1.3. Online Pharmacies
  • 9.5. Latin America Non-infectious Macular Edema Treatment Market Outlook, by Country, Value (US$ Mn) and Volume, 2018 - 2031
    • 9.5.1. Key Highlights
      • 9.5.1.1. Brazil Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.2. Brazil Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.3. Brazil Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.4. Brazil Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.5. Mexico Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.6. Mexico Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.7. Mexico Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.8. Mexico Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.9. Argentina Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.10. Argentina Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.11. Argentina Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.12. Argentina Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.13. Rest of Latin America Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.14. Rest of Latin America Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.15. Rest of Latin America Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.16. Rest of Latin America Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 9.5.2. BPS Analysis/Market Attractiveness Analysis

10. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031

  • 10.1. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.1.1. Key Highlights
      • 10.1.1.1. Anti-VEGF
      • 10.1.1.2. Corticosteroids
      • 10.1.1.3. Immunosuppressant
      • 10.1.1.4. Biologics
      • 10.1.1.5. Others
  • 10.2. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.2.1. Key Highlights
      • 10.2.1.1. Non-infectious Uveitic Macular Edema
      • 10.2.1.2. Diabetic Macular Edema
      • 10.2.1.3. Retinal Vein Occlusion with Macular Edema
  • 10.3. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.3.1. Key Highlights
      • 10.3.1.1. Oral
      • 10.3.1.2. Parenteral
      • 10.3.1.3. Topical
  • 10.4. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.4.1. Key Highlights
      • 10.4.1.1. Hospital Pharmacies
      • 10.4.1.2. Retail Pharmacies
      • 10.4.1.3. Online Pharmacies
  • 10.5. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, by Country, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.5.1. Key Highlights
      • 10.5.1.1. GCC Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.2. GCC Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.3. GCC Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.4. GCC Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.5. South Africa Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.6. South Africa Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.7. South Africa Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.8. South Africa Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.9. Egypt Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.10. Egypt Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.11. Egypt Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.12. Egypt Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.13. Nigeria Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.14. Nigeria Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.15. Nigeria Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.16. Nigeria Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.17. Rest of Middle East & Africa Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.18. Rest of Middle East & Africa Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.19. Rest of Middle East & Africa Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.20. Rest of Middle East & Africa Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.5.2. BPS Analysis/Market Attractiveness Analysis

11. Competitive Landscape

  • 11.1. Product vs Indication Heatmap
  • 11.2. Company Market Share Analysis, 2023
  • 11.3. Competitive Dashboard
  • 11.4. Company Profiles
    • 11.4.1. Pfizer, Inc.
      • 11.4.1.1. Company Overview
      • 11.4.1.2. Product Portfolio
      • 11.4.1.3. Financial Overview
      • 11.4.1.4. Business Strategies and Development
    • 11.4.2. Novartis AG
      • 11.4.2.1. Company Overview
      • 11.4.2.2. Product Portfolio
      • 11.4.2.3. Financial Overview
      • 11.4.2.4. Business Strategies and Development
    • 11.4.3. F. Hoffman - La Roche Ltd.
      • 11.4.3.1. Company Overview
      • 11.4.3.2. Product Portfolio
      • 11.4.3.3. Financial Overview
      • 11.4.3.4. Business Strategies and Development
    • 11.4.4. AbbVie Inc
      • 11.4.4.1. Company Overview
      • 11.4.4.2. Product Portfolio
      • 11.4.4.3. Financial Overview
      • 11.4.4.4. Business Strategies and Development
    • 11.4.5. Bayer AG
      • 11.4.5.1. Company Overview
      • 11.4.5.2. Product Portfolio
      • 11.4.5.3. Financial Overview
      • 11.4.5.4. Business Strategies and Development
    • 11.4.6. Valeant Pharmaceuticals Inc
      • 11.4.6.1. Company Overview
      • 11.4.6.2. Product Portfolio
      • 11.4.6.3. Financial Overview
      • 11.4.6.4. Business Strategies and Development
    • 11.4.7. Alimera Sciences Inc
      • 11.4.7.1. Company Overview
      • 11.4.7.2. Product Portfolio
      • 11.4.7.3. Financial Overview
      • 11.4.7.4. Business Strategies and Development
    • 11.4.8. Clearside Biomedical, Inc
      • 11.4.8.1. Company Overview
      • 11.4.8.2. Product Portfolio
      • 11.4.8.3. Financial Overview
      • 11.4.8.4. Business Strategies and Development

12. Appendix

  • 12.1. Research Methodology
  • 12.2. Report Assumptions
  • 12.3. Acronyms and Abbreviations